Paramyxovirus strategies for evading the interferon response
β Scribed by Bin Gotoh; Takayuki Komatsu; Kenji Takeuchi; Junko Yokoo
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 310 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1052-9276
- DOI
- 10.1002/rmv.357
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
Two genera, the Respirovirus (Sendai virus (SeV) and human parainfluenza virus (hPIV3) and the Rubulavirus (simian virus (SV) 5, SV41, mumps virus and hPIV2), of the three in the subfamily Paramyxovirinae inhibit interferon (IFN) signalling to circumvent the IFN response. The viral protein responsible for the inhibition is the C protein for respirovirus SeV and the V protein for the rubulaviruses, both of which are multifunctional accessory proteins expressed from the P gene. SeV suppresses IFNβstimulated tyrosine phosphorylation of signal transducers and activators of transcription (STATs) at an early phase of infection and further inhibits the downstream signalling without degrading any of the signalling components in most cell lines. On the contrary, the Rubulavirus V protein targets Stat1 or Stat2 for degradation. Proteasomeβmediated degradation appears to be involved in most cases. Studies on the molecular mechanisms by which paramyxoviruses evade the IFN response will offer important information for modulating the JAKβSTAT pathway, designing novel antiviral drugs and recombinant live vaccines, and improving paramyxovirus expression vectors for gene therapy. Copyright Β© 2002 John Wiley & Sons, Ltd.
π SIMILAR VOLUMES
T18d of BALB/c mice is a member of the Tla category of class I genes of the major histocompatibility complex of the mouse and is highly restricted in expression. Deletion analysis implies that an element essential to T18d expression resides within the region -4 to +54. The homologous region of T3d,
238 patients with squamous cell carcinoma of the upper aerodigestive tract were given 3 cycles of chemotherapy [cisplatinurn (cis-DDP), 100 rngl m2 on day 1 ; 5-fluorouracil (5-FU), 1,000 mg/m2 on days 2-61 before any local treatment. Eighty-one of these patients had pharyngolaryngeal cancer. O f th